Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merrimack Initiates Phase I MM-398 Trial | Contract Pharma

What are you searching for?

Sign in

Merrimack Initiates Phase I MM-398 Trial

To evaluate cyclophosphamide combination in pediatric tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merrimack Pharmaceuticals has initiated a Phase I dose-escalating trial of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors. Preclinical research suggests MM-398 administration results in sustained delivery of larger quantities of chemotherapy as compared to conventional administration.
 
The Phase I study will assess the safety of MM-398 and will determine the recommended Phase II dose. Approximately 40 patients from 1 to 21 years are expected to be enrolled.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics